Saudi Arabia medical devices market: size, growth and outlook 2026–2032

The largest device market in the GCC, now paying suppliers to localise. Published estimates normalised to 2025 range from USD 2.7 bn to USD 6.5 bn; the Consulting Wallah central estimate is USD 5.2 bn, growing at about 5% a year to USD 7.5 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by vision 2030 healthcare infrastructure: >USD 65 bn planned incl. 21 health clusters; SAR 260 bn health & social budget in 2025; rising chronic disease burden (18.95% of adults 15+ with a chronic disease, GASTAT 2024; NCDs ~35% of deaths); centralised public procurement through NUPCO framework agreements (direct tender ~75% of channel).

Context that matters for buyers and suppliers: Saudi Arabia imports nearly 90% of its medical device requirements. NUPCO serves >500 public hospitals/health centres; supplied 7,919 medical items to 47 government health agencies in a year; national factories' share of NUPCO procurement 17.6%. SFDA MDMA registration required for all classes A-D via GHAD system; technical-file (MDMA 2) pathway since Jan 2022; ISO 13485 required for local suppliers. Made in Saudi requires 40% local value-add; local content mandatory in NUPCO tenders; contracts <= SAR 1 mn exempt from local-content preference.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 2.7 bn–USD 6.5 bn; differences are mostly scope.

Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Saudi Arabia imports nearly 90% of its medical device requirements (P&S Market Research / TechSci)
• NUPCO serves >500 public hospitals/health centres; supplied 7,919 medical items to 47 government health agencies in a year; national factories' share of NUPCO procurement 17.6% (MedDeviceGuide)
• SFDA MDMA registration required for all classes A-D via GHAD system; technical-file (MDMA 2) pathway since Jan 2022; ISO 13485 required for local suppliers (MedDeviceGuide)
• Made in Saudi requires 40% local value-add; local content mandatory in NUPCO tenders; contracts <= SAR 1 mn exempt from local-content preference (MedDeviceGuide)
• Pharma localisation target 80% of production by 2030; 40 factories cover ~36% of demand (MedDeviceGuide)
• In 2025 ~87% of SFDA local-manufacturing inspections covered low and moderate-low risk products (SFDA via TechSci Research)
• Saudi Arabia accounts for ~60% of GCC healthcare expenditure (ITA via P&S / Meticulous)
• Hospitals & ASCs 70% of end-user demand; direct tender 75% of distribution; Riyadh 35% of market (2025) (P&S Market Research)

Where the GCC and India sit

• Saudi Arabia share of GCC healthcare spending: 60% (2025) — US International Trade Administration via Meticulous / P&S
• Saudi health & social development budget: SAR 260 bn (USD 69 bn) (2025) — P&S Market Research
• Saudi healthcare allocation: SAR 214 bn (~USD 57.1 bn) (2024) — ITA via TechSci Research
• NUPCO annual procurement: > SAR 25 bn (~USD 6.7 bn) (2026) — MedDeviceGuide
• Healthcare deals signed at Global Health Exhibition Riyadh: USD 35.5 bn (2025) — TechSci Research

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: localisation: Invest Saudi projects device localisation adds SAR 1.7 bn to GDP and ~7,300 jobs by 2030; made in Saudi programme (40% local value-add) and NUPCO local-content preferences favour local assembly/JV partners; aI and digital health investment >SAR 13.3 bn; SFDA MDS-G010 guidance on AI/ML devices.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers and exporters: registration first, local partner second, tender readiness third — see what GCC buyers need.
• Hospital leaders: total cost of ownership (service, consumables, software) outweighs purchase price; tender the bundle.
• Investors: local assembly and distribution platforms backed by procurement preference.

1. P&S Market Research, Saudi Arabia Medical Devices Market Report (2019-2032) — psmarketresearch.com
2. TechSci Research, Saudi Arabia Medical Devices Market Forecast 2031 — techsciresearch.com
3. Meticulous Research, Saudi Arabia Medical Devices Market press release — meticulousresearch.com
4. MedDeviceGuide, Saudi Arabia NUPCO Medical Device Procurement Guide — meddeviceguide.com
5. P&S Market Research (2025-10) — USD 6.5 bn (2025) to USD 9.1 bn (2032), CAGR 5.0% (2026-2032); scope: country / all medical devices; 2026 est. USD 6.8 bn — source
6. TechSci Research (2026) — USD 2.71 bn (2025) to USD 3.79 bn (2031), CAGR 5.75% (2026-2031); scope: country / medical devices (narrower scope than P&S) — source
7. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
8. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.